SAB Biotherapeutics
SABSSAB Biotherapeutics (NASDAQ: SABS) is a clinical-stage biopharmaceutical company based in the United States. Its primary business focus is the development of the DiversitAb™ platform, a proprietary technology designed to produce fully human polyclonal antibodies. This approach utilizes transgenic cattle that have been genetically engineered to generate a broad, diverse, and targeted human antibody response when immunized with specific antigens. The company's objective is to harness this natural immune response to create therapeutic candidates. The company’s pipeline targets immune and infectious diseases. Its lead product candidate, SAB-142, is being developed for the treatment of type 1 diabetes, with the goal of modulating the autoimmune response without causing broad immunosuppression. SAB Biotherapeutics has also advanced programs for infectious diseases, having previously conducted clinical trials for a polyclonal antibody therapeutic against SARS-CoV-2. The platform is positioned to address conditions where a complex, polyclonal antibody response may be more efficacious than single-target monoclonal antibodies. As a publicly traded entity, SAB Biotherapeutics continues to conduct clinical-stage research to validate its platform and therapeutic candidates. The company’s work centers on translating the DiversitAb™ platform into clinical products for areas with significant unmet medical need, focusing on the inherent advantages of naturally generated, high-potency human polyclonal antibodies.
SABS · Stock Price
Historical price data
About
SAB Biotherapeutics (NASDAQ: SABS) is a clinical-stage biopharmaceutical company based in the United States. Its primary business focus is the development of the DiversitAb™ platform, a proprietary technology designed to produce fully human polyclonal antibodies. This approach utilizes transgenic cattle that have been genetically engineered to generate a broad, diverse, and targeted human antibody response when immunized with specific antigens. The company's objective is to harness this natural immune response to create therapeutic candidates. The company’s pipeline targets immune and infectious diseases. Its lead product candidate, SAB-142, is being developed for the treatment of type 1 diabetes, with the goal of modulating the autoimmune response without causing broad immunosuppression. SAB Biotherapeutics has also advanced programs for infectious diseases, having previously conducted clinical trials for a polyclonal antibody therapeutic against SARS-CoV-2. The platform is positioned to address conditions where a complex, polyclonal antibody response may be more efficacious than single-target monoclonal antibodies. As a publicly traded entity, SAB Biotherapeutics continues to conduct clinical-stage research to validate its platform and therapeutic candidates. The company’s work centers on translating the DiversitAb™ platform into clinical products for areas with significant unmet medical need, focusing on the inherent advantages of naturally generated, high-potency human polyclonal antibodies.